Matching-Assisted Power Prior for Incorporating Real-World Data in Randomized Clinical Trial Analysis.

Leveraging external data information to supplement randomized clinical trials has been a popular topic in recent years, especially for medical device and drug discovery. In rare diseases, it is very challenging to recruit patients and run a large-scale randomized trial. To take advantage of real-world data from historical trials on the same disease, we can run a small hybrid trial and borrow historical controls to increase the power.

Cross-patient seizure prediction via continuous domain adaptation and similar sample replay.

Seizure prediction based on electroencephalogram (EEG) for people with epilepsy, a common brain disorder worldwide, has great potential for life quality improvement. To alleviate the high degree of heterogeneity among patients, several works have attempted to learn common seizure feature distributions based on the idea of domain adaptation to enhance the generalization ability of the model. However, existing methods ignore the inherent inter-patient discrepancy within the source patients, resulting in disjointed distributions that impede effective domain alignment.

Hybrid Membrane Biomimetic Photothermal Nanorobots for Enhanced Chemodynamic-Chemotherapy-Immunotherapy.

Glioblastoma multiforme (GBM) is a highly invasive and fatal brain tumor with a grim prognosis, where current treatment modalities, including postoperative radiotherapy and temozolomide chemotherapy, yield a median survival of only 15 months. The challenges of tumor heterogeneity, drug resistance, and the blood-brain barrier necessitate innovative therapeutic approaches. This study introduces a strategy employing biomimetic magnetic nanorobots encapsulated with hybrid membranes derived from platelets and M1 macrophages to enhance blood-brain barrier penetration and target GBM.

DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.

Intervening in mitochondrial oxidative phosphorylation (OXPHOS) has emerged as a potential therapeutic strategy for certain types of cancers. Employing kinome-based CRISPR screen, we find that knockout of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) synergizes with OXPHOS inhibitor IACS-010759 in liver cancer cells. Targeting DYRK1A combined with OXPHOS inhibitors activates TGF-β signaling, which is crucial for OXPHOS-inhibition-triggered cell death.

HERC5/ISG15 Enhances Glioblastoma Stemness and Tumor Progression by mediating SERBP1protein stability.

Glioblastoma (GBM) is the most common malignant brain tumor, and has a low survival rate and a poor prognosis. Intensive studies of pathogenic mechanisms are essential for exploring therapeutic targets for GBM. In this study, the roles played by interferon-stimulated gene 15 (ISG15), HECT, RCC1-containing protein 5 (HERC5), and SERPINE1 mRNA binding protein 1 (SERBP1) in regulating GBM cell stemness were investigated.